Inhibace (Cilazapril)

Cilazapril blocks the angiotensin‑converting enzyme, which stops the formation of angiotensin II, a molecule that narrows blood vessels and stimulates aldosterone release. By reducing angiotensin II levels, blood vessels relax, blood pressure falls, and the heart experiences less strain.

The exact dose of Inhibace is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and renal function. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Cilazapril is generally not recommended during pregnancy because ACE inhibitors can affect fetal kidney development and cause injury. Safety during breastfeeding has not been fully established, so the drug should only be used if the potential benefit outweighs the risk, under medical supervision.

To request Inhibace, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Inhibace (cilazapril) shares the same mechanism as other ACE inhibitors such as enalapril or lisinopril, providing blood‑pressure reduction and heart‑failure benefits. Differences may lie in pharmacokinetic profiles, dosing frequency, and individual tolerability, which are evaluated by the prescriber to select the most appropriate agent for each patient.

Inhibace should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Inhibace is taken orally, usually as a tablet, with or without food as directed by the healthcare provider. The tablet should be swallowed whole with a glass of water; it is not intended for crushing, chewing, or sublingual administration.

The most serious adverse reactions to monitor include angioedema (swelling of the face, lips, tongue, or throat), severe hypotension, hyperkalemia, and acute kidney injury. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden dizziness, or a marked drop in urine output.

Inhibace is contraindicated in individuals with a known hypersensitivity to cilazapril or any ACE inhibitor, a history of angioedema related to ACE‑inhibitor therapy, and in patients with hereditary or idiopathic angioedema. Caution is also advised for those with severe renal impairment or bilateral renal artery stenosis.